Carvedilol is not superior to metoprolol for heart failure patients when given at equivalent doses by Gorman, Adam
Clinical Research in Practice: The Journal
of Team Hippocrates
Volume 5 | Issue 2 Article 9
2019
Carvedilol is not superior to metoprolol for heart
failure patients when given at equivalent doses
Adam Gorman
Wayne State University School of Medicine, agorman@med.wayne.edu
Follow this and additional works at: https://digitalcommons.wayne.edu/crp
Part of the Medical Education Commons, and the Translational Medical Research Commons
This Critical Analysis is brought to you for free and open access by the Open Access Journals at DigitalCommons@WayneState. It has been accepted
for inclusion in Clinical Research in Practice: The Journal of Team Hippocrates by an authorized editor of DigitalCommons@WayneState.
Recommended Citation
GORMAN A. Carvedilol is not superior to metoprolol for heart failure patients when given at equivalent doses. Clin. Res. Prac. 2019
Sep 12;5(2):eP1891. doi: 10.22237/crp/1567555680
 
VOL 5 ISS 2 / eP1891 / SEPTEMBER 12, 2019 
doi: 10.22237/crp/1567555680 
 




http://digitalcommons.wayne.edu/crp, © 2019 The Author(s) 
1 Licensed under Creative Commons Attribution Non-Commercial 4.0 
 
Carvedilol is not superior to metoprolol for 
heart failure patients when given at 
equivalent doses 
ADAM GORMAN, Wayne State University School of Medicine, agorman@med.wayne.edu 
 
ABSTRACT A critical appraisal and clinical application of Lazarus DL, Jackevicius CA, Behlouli H, et al. Population-Based Analysis 
of Class Effect of β Blockers in Heart Failure. The American Journal of Cardiology 2011;107(8):1196-1202. doi: 
10.1016/j.amjcard.2010.12.017. 
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Clinical Context 
Mary Garcia (pseudonym) was a 91-year-old woman with a history significant for congestive heart failure with 
reduced ejection fraction of 20%, hypertension, CABG procedure with drug eluting stent placement, and 
biventricular ICD placement. She presented to the emergency room due  to an exacerbation of shortness of breath 
that she had been experiencing over the last month. She described this issue as inhibiting acts of daily living, such 
as ambulating around her apartment and cooking for herself, which she was able to do at her baseline. She 
mentioned that recently taking food out of the oven caused her to need to hold onto the counter to catch her 
breath. This was concerning for her because she was very proud to live independently in her own apartment with 
only some help from a grandson who visited a few times a week. 
There was an interest from the hospital teams taking care of her to change her medication regimen to better 
control her symptoms, reduce her mortality risk associated with her heart failure, and lower her blood pressur e 
from the elevated 181/82 it was on admission. Her daily cardiovascular medications were aspirin 81 mg, 
atorvastatin 20 mg, furosemide 40 mg, losartan 25 mg, spironolactone 12.5 mg, and metoprolol 50 mg. Everyone 
agreed that part of her therapy should continue to include a beta blocker, as this has been shown to decrease 
mortality in heart failure patients according to AHA/ACC guidelines.1 However, there was disagreement about 
which one to use. One consulting team wanted to try to increase her metoprolol dose she was on at home from 50 
mg daily to 200 mg daily, and the other consulting team wanted to switch her metoprolol to carvedilol 12.5 mg 
twice a day. Ms. Garcia was interested in trying any treatment that would help her be more independent again and 
give her more time alive to spend with her grandchildren. 
Clinical Question 
Is there a difference between carvedilol or metoprolol effects on all-cause mortality in heart failure patients when the medications 
are given at equivalent doses? 
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Research Article 
Lazarus DL, Jackevicius CA, Behlouli H, et al. Population-Based Analysis of Class Effect of β Blockers in Heart Failure. The American 
Journal of Cardiology 2011;107(8):1196-1202. doi: 10.1016/j.amjcard.2010.12.017 
Related Literature 
A general search of PubMed was done looking for the terms “carvedilol,” “metoprolol,” “Heart Failure,” and “Mortality” for 
randomized control trials and retrospective or prospective cohort studies. Systemic reviews were analyzed to seek the most relevant 
studies. Publications that focused on subsets of heart failure with additional co-morbidities, like patients on hemodialysis, were 
excluded. 
The most recent review found was a 2015 meta-analysis, published by Briasoulis et al.2, directly investigated the clinical question for 
our patient of a potential advantage between carvedilol or metoprolol effects on all -cause mortality with heart failure patients. This 
review was very well designed with comprehensive study searches done and use of the Cochrane risk-of-bias tool to eliminate 
studies with a high risk of bias. The Briasoulis review also incorporated an exclusion criteria that included elimination of studies that 
tested low doses of the beta blockers in question, which they set to carvedilol <= 12.5 mg/day and metoprolol <= 100 mg/day. That 
review found four articles that met the criteria of comparing both medications at high doses and not having a high risk of bi as: Shore 
et al.3, Pasternak et al.4, Bolling et al.5, and Lazarus et al.6. Its conclusion was that there was no significant difference between the 
two drugs. 
The most substantial study that was excluded was the “Carvedilol Or Metoprolol European Trial“ (COMET) of 2003 .7 This was a 
double-blind randomized parallel group trial of 1,511 patients with chronic heart failure treated with either 50 mg of carvedilol da ily 
or 100 mg of metoprolol daily. This article found that the patients taking carvedilol had a lower all -cause mortality rate than the 
patients taking metoprolol. However, as was discussed in the most recent meta-analysis, this trial was comparing a metoprolol given 
at a low dose to carvedilol given at a high dose, so it was not included in this literature search. While a randomized contro l trial 
would have been ideal to have been analyzed for this appraisal, this one did not compare equivalent doses of me dications. 
Shore et al. evaluated 3,716 patients with heart failure NYHA class 3 or worse. It compared patients on carvedilol and metopr olol 
succinate over the course of 10 years. This study did find any significant different between the two drugs in all -cause mortality, 
baseline ejection fraction, or repeat hospitalizations in both patients with ischemic and non -ischemic heart failure.3 
Pasternak et al. conducted a cohort study that evaluated 11,664 patients with heart failure with reduced ejection fraction on 
guideline determined medical treatment. 6,026 of them received carvedilol and 5638 received metoprolol succinate. The results  did 
not show a significant absolute risk difference between the two treatments, and this was true acr oss all different NYHA 
classifications. However, only 52% of patients on carvedilol and 12% of metoprolol users reached the recommended daily target  
doses of 50 mg and 200 mg daily respectively.4 
Bolling et al. conducted a retrospective cohort study that investigated 58,634 patients who initiated beta-blocker treatment within 
60 days of discharge from admission due to heart failure. This paper showed that carvedilol was associated with lower mortali ty 
rates than metoprolol at the higher doses. However, the article also stated that the patients receiving carvedilol were younger, had 
less co-morbidities, and were receiving more concomitant treatments, like angiotensin-converting enzyme (ACE)-inhibitors and 
statins. All three of those differences could potentially explain the difference in mortality.5 
Lazarus et al. investigated 26,787 patients with congestive heart failure. It is a study that adjusted for age, initial beta-blocker dose, 
co-morbidities, drugs prescribed at discharge, interval to the filling of the first prescription, and other factors. Because this study 
took into account these factors and utilized such a large sample size, it was chosen for critical appraisal. A double -blinded, placebo-
controlled trial could not have been chosen in this case because none were available that tested high doses of both medications and 
had a low risk of bias according to the Briasoulis et al. analysis.6 There are newer studies, such as Perreault et al.8, that have similar 
findings and similar study designs, but they included less patients than this one did. 
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Critical Appraisal 
This study was an observational cohort study that used data from the Quebec government administrative and prescription claims 
databases. The investigators collected their data from patients admitted to the hospital with a primary diagnosis of heart fa ilure as 
described by ICD codes. They only included patients who were at least 65 years old who had not been admitted to the hospital 
within 3 years of the study period and who filled their prescription for a beta blocker within 90 days after discharge. Patie nts were 
categorized based on the beta blocker they were prescribed, which were metoprolo l, atenolol, carvedilol, and acebutolol. 
Adherence to therapy was measured by recording percentage of days that a patient was covered by a beta blocker prescription 
during the year after discharge or until death if that came first. 
The primary outcome that the researchers were interested in was mortality at any point during the follow up period. A secondary 
outcome that was also tracked was readmissions because of heart failure, which was also checked using ICD codes. For each pat ient, 
prescriptions of non-over-the-counter medications, co-morbidity information, length of hospital stay, medical procedures received 
between admission and first beta blocker prescription filling (e.g. catheterization), and the specialty of the admitting phys ician were 
also collected. 
Once the data was collected, it was analyzed using various statistical techniques. The Kaplan-Meier method was used to calculate 
the unadjusted mortalities for the patients on each of the different beta blockers. The investigators used a multivariable  Cox 
proportional hazards model to allow them to account for differences in patient characteristics, like patient age and dosage o f beta 
blocker, as described in the previous section. Their target dosage for beta blockers included 200 mg/day for metoprolol  and 50 
mg/day for carvedilol, which are both higher doses. 
This study had a large number of various results, but the most relevant for our clinical question was the comparison between the 
metoprolol and carvedilol groups. Patients prescribed metoprolol ac counted for ~54% of the patients in the study and patients 
prescribed carvedilol accounted for only ~8%. There was similar adherence to therapy across both groups of patients with the 
carvedilol patients being at 83% and the metoprolol patients being at 81%. The patients on carvedilol had similar use of most heart 
failure medications like ACE inhibitors and statins to those on metoprolol, although that cohort did have higher use of 
spironolactone and digoxin. 
The final results after analysis showed no significant difference in mortality or readmission outcomes, although the carvedilol group 
had slightly lower rates. These results did not change after stratifying patients according to hypertension of myocardial inf arction co-
morbidities. Interestingly, the study did find an advantage when prescribing patients low-lipid soluble beta blockers like atenolol and 
acebutolol. For example, atenelol when compared to metoprolol had lower mortality rates (HR 0.82, 95% CI 0.77 to 0.87, p <0.0 01) 
and combined mortality-readmission rates (HR 0.84, 95% CI 0.79 to 0.89, p <0.001), however this result was not as relevant to our 
clinical question. 
Since this was a cohort study, this study is somewhat limited in its ability to create clinical recommendations. The authors did 
acknowledge some selection bias with the absence of randomization among the groups. They also had no way of differentiating 
patients depending on severity of their heart failure, which could either be measured through determining its stage or class or by 
comparing ejection fractions, as they only were able to look at the ICD code for heart failure. A randomized -control, double-blinded 
trial would give the best evidence to support the authors’ conclusion that, when given at a high dose, there is no significan t 
difference between carvedilol and metoprolol. This paper was determined to be at a 2b level of evidence according to the Oxfo rd 
Centre for Evidence-based Medicine Levels of Evidence. 
Clinical Application 
In the case of Ms. Garcia, the 91-year-old lady with a history of congestive heart failure on low-dose metoprolol in 
addition to other medications, there was no advantage in switching to carvedilol instead of just raising the 
metoprolol dose. The literature on this topic showed that there is not a significant decrease in all-cause mortality 
between the two treatments assuming that both are prescribed in a high dose. In the case of this patient 
specifically, Ms. Garcia stated that she would also be more comfortable taking a higher dose of a medication that 
she is used to taking instead of switching to a different one. For those reasons, the best course of action was to 
increase her metoprolol dose to 200 mg per day. 
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Learning points: 
1. There is no significant difference between metoprolol and carvedilol in decreasing mortality in patients with 
congestive heart failure. 
2. Beta blockers should be given at high doses instead of low doses for equal reduction in mortality risk.  
3. Medications can be more or less efficacious depending on dosing and that should be taken into account along 
with their drug class. 
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